Hori K, Saito S
Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan.
Br J Cancer. 2004 Jan 26;90(2):549-53. doi: 10.1038/sj.bjc.6601582.
AVE8062, a derivative of combretastatin A-4, has a strong stanching effect on tumour blood flow (TBF), which leads to complete blockage of nutrient supply to solid tumours and their necrosis. Previously, we reported that TBF stasis is due to increased arteriolar resistance caused by AVE8062 and a lasting decrease in perfusion pressure in tumour-feeding vessels. Here, we measured changes in TBF in rat solid tumour LY80 during continuous administration of AVE8062-like epinephrine or four catecholamines that are unlike AVE8062 (norepinephrine, dopamine, methoxamine, and metaraminol) to the region of increased vascular resistance. Venous administration of 0.3 mg ml(-1) epinephrine caused TBF to fall immediately to near zero, where it remained throughout the administration period. With a 30-min drug administration, TBF began to recover immediately when drug administration halted. With a 60-min epinephrine administration, TBF recovered somewhat, but not to the previous level. With drug administration of 120 min, TBF did not recover during the subsequent 8 h. Likewise, 0.1 mg ml(-1) epinephrine produced irreversible occlusion after 120 min of administration. In contrast, 120 min of administration of the four other catecholamines resulted in no occlusion. Only the group given 0.3 mg ml(-1) epinephrine (not that given methoxamine) showed significantly greater necrosis than the control. We conclude that, for epinephrine to cause irreversible occlusion of these vessels, a marked decrease in perfusion pressure in tumour-feeding blood vessels is necessary and should be maintained for 2 h. This conclusion is consistent with the previously demonstrated mechanism of irreversible arteriole occlusion caused by AVE8062. AVE8062 and epinephrine appear to have the same mechanism of action regarding induction of tumour blood flow stasis.
AVE8062是康普瑞汀A - 4的衍生物,对肿瘤血流(TBF)有很强的止血作用,这会导致实体瘤的营养供应完全阻断并使其坏死。此前,我们报道TBF停滞是由于AVE8062引起的小动脉阻力增加以及肿瘤供血血管灌注压的持续降低。在此,我们在向血管阻力增加区域持续输注类似AVE8062的肾上腺素或四种与AVE8062不同的儿茶酚胺(去甲肾上腺素、多巴胺、甲氧明和间羟胺)期间,测量了大鼠实体瘤LY80中的TBF变化。静脉注射0.3 mg ml⁻¹肾上腺素会使TBF立即降至接近零,并在整个给药期间保持在该水平。给药30分钟后,停药时TBF立即开始恢复。给予肾上腺素60分钟后,TBF有所恢复,但未恢复到先前水平。给予药物120分钟后,TBF在随后的8小时内未恢复。同样,0.1 mg ml⁻¹肾上腺素给药120分钟后产生不可逆阻塞。相比之下,其他四种儿茶酚胺给药120分钟均未导致阻塞。只有给予0.3 mg ml⁻¹肾上腺素的组(而非给予甲氧明的组)显示出比对照组明显更大的坏死。我们得出结论,要使肾上腺素导致这些血管的不可逆阻塞,肿瘤供血血管的灌注压必须显著降低并应维持2小时。这一结论与先前证明的AVE8062引起不可逆小动脉阻塞的机制一致。AVE8062和肾上腺素在诱导肿瘤血流停滞方面似乎具有相同的作用机制。